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Immunosuppression
PhosphorylationCyclosporine A and FK506 produce immunosuppression by blocking calcineurin phosphatase activity and
consequently activation of cytosolic Nuclear Factor of Activated T-cell (NFATc) transcription factor. Due to
the chronic toxicity associated with their administration, the development of more speciﬁc immunosuppres-
sants is currently an important unmet medical need. In this context, an immunosuppressant peptide derived
from the CIC motif of the human Regulators of Calcineurin (RCAN) proteins has been shown to inhibit NFATc
signaling without affecting general phosphatase activity of calcineurin. Here we show that protein kinase CK2
phosphorylates a conserved serine residue within the CIC motif of vertebrate RCANs, which increases its af-
ﬁnity for calcineurin and consequently its inhibition of NFATc-dependent gene expression in activated
T-cells. Molecular modeling studies have led us to identify a positively charged interaction site on the surface
of calcineurin where the phosphorylated serine residue of the CIC motif would normally locate. Finally, we
have also identiﬁed RCAN3 as a new phosphoprotein with multiple phosphorylation sites. Therefore, our
ﬁndings reveal for the ﬁrst time a novel molecular mechanism underlying the regulation of calcineurin–
NFATc signaling by means of phosphorylation of the CIC motif of RCAN proteins. The knowledge of how
RCAN proteins modulate the calcineurin–NFATc pathway paves the way for the development of potent
novel selective immunosuppressant drugs.
© 2013 Published by Elsevier B.V.1. Introduction
The highly conserved serine/threonine phosphatase calcineurin
(Cn, also known as PPP3, formerly PP2B) is a cellular sensor enzyme
that plays a pivotal role in transducing Ca2+ signals into cellular re-
sponses [1]. The activation of Cn, which is ubiquitously expressed,
results in the dephosphorylation of its substrates, including the cyto-
solic members of the Nuclear Factor of Activated T-cell (NFATc) fam-
ily of transcription factors [2]. Once dephosphorylated, NFATc
proteins translocate to the nucleus where, in cooperation with otherlytic subunit A; CIC sequence,
ence; CK2, protein kinase CK2;
AN, Regulators of Calcineurin;
tate 13-acetate
aboratory, Cancer and Molecular
te — IDIBELL. L'Hospitalet de
x: +34 932607414.
sevier B.V.transcription factors, they trigger the expression of genes involved
in diverse biological processes including T-cell activation, cardiac hy-
pertrophy, bone remodeling or angiogenesis among others [3]. The
importance of this pathway came to light with the discovery that
the most widely used current immunosuppressant drugs, cyclospor-
ine A (CsA) and FK506, elicited their clinical response by inhibiting
Cn enzymatic activity and therefore also activation of NFATc [4].
However, further studies revealed that the inhibition of Cn by these
drugs inhibits dephosphorylation of all Cn substrates and is associat-
ed to severe undesirable side effects [5].
The Regulators of Calcineurin (RCAN; previously called DSCR,
MCIP or calcipressin (CALP)) family of proteins are speciﬁc endoge-
nous modulators of the Cn–NFATc signaling axis [6,7]. This protein
family, deﬁned by several highly conserved motifs in Eukarya such
as the FLISPP motif (FLISPPASPP sequence), is conserved from yeast
to human and in vertebrates constitutes a highly conserved subfamily
comprised of three proteins: RCAN1, RCAN2 and RCAN3 [8,9], each of
which is expressed as different isoforms [9]. The speciﬁcity towards
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conserved Cn-interactingmotifs shared by both NFATc and RCAN pro-
teins: the LXXP (LXVP in NFATc proteins) and PXIXIT motifs [10–14].
The PXIXIT motif has been described as the major Cn-anchoring site of
NFATc proteins [15]. The crystal structure of the synthetic VIVIT peptide
derived from the PXIXIT sequence of NFATc [16] in complex with Cn,
helped to clarify how this sequence interacts in a hydrophobic cleft
formed by strands β14 and β11 of Cn [17]. Variations in the consensus
PXIXIT sequence modulate the binding afﬁnity for Cn of the different
PXIXIT-containing proteins and therefore the biological consequence
of such interaction [18–20]. RCAN proteins possess a PSVVVH sequence
which has been shown to behave as a PXIXITmotif [12–14]. This PXIXIT
sequence, together with a C-terminal ELHA sequence, comprise the
RCAN inhibitor of Cn (CIC) motif, conserved in all vertebrate RCANs
[8,21]. We and others have shown that in RCANs, the CIC motif needs
both the ELHA and PXIXIT sequences to bind with high afﬁnity to Cn
and inhibit downstream NFATc signaling [12,14].
Both inhibitory and facilitative roles on the Cn–NFATc signaling
pathway have been associated with the RCANs, depending on the spe-
ciﬁc tissue or cell type and expression level [22–24]. In addition, RCAN
proteins are also known to be regulated by post-translational modiﬁca-
tion including phosphorylation. For instance, phosphorylation at the
conserved FLISPPmotif of RCAN1 byGSK3β, primed by phosphorylation
by either BMK, MAPK or DYRK1A, facilitates Cn–NFATc signaling
[25–28]. Also, phosphorylation of RCAN1 by TAK1 has been related to
a facilitative role towards the Cn–NFATc signaling pathway [29]. On
the other hand, phosphorylated RCAN1 at both serine residues of the
FLISPP motif has been shown to be a better inhibitor of NFATc activity
[26]. In addition, phosphorylation of RCAN1 has also been associated
to an increased protein half life and therefore and enhanced inhibition
of Cn–NFATc signaling [28,30].
Protein kinase CK2 is a ubiquitous enzyme with pleiotropic activ-
ity, as it has been shown to phosphorylate many substrates, including
NFATc [31,32]. CK2 consists of two catalytic (α or α′) and two β reg-
ulatory subunits arranged as a tetramer [33]. Although it is generally
regarded as a constitutively active enzyme, some natural regulators of
its activity have been described [34]. In this work, we identify a phos-
phorylated serine within a protein kinase CK2 consensus sequence at
the conserved CIC motif in all vertebrate RCANs. Additionally, we
show that this phosphorylation increases the afﬁnity of the CIC
motif of RCAN for Cn and consequently potentiates the inhibition to-
wards Cn–NFATc pathway activation and T-cell activation.
2. Materials and methods
2.1. Peptides and reagents
All peptides were purchased from the Peptide 2.0 Company
(Chantilly, VA) and synthesized as acetylated N-terminal and
C-terminal amides for the unlabeled peptides and N-carboxyﬂuorescein
(CF) and C-terminal amide for the labeled peptides. The sequences
of the peptides used are the following: KYELHAGTESTPSVVVHVCES
for the RCAN183–203 peptides; KYELHAGTESTPSVVVHVCESETEEE for
the RCAN3183–208 peptides; KYELHAGTESTPSVVVHVCE(pS)ETEEE for
the phosphoRCAN3183–208 peptides; ASGLSPRIEITPSHEL for the
NFATc2-SPRIEIT (SPRIEIT) peptides; MAGPHPVIVITGPHEE for the
VIVIT peptide; and MAGPHPVIVITGPHAA for the mutated VIVIT
(VIVIT–AA) peptide. The N-termini CF-labeled peptides were syn-
thesized with a two-glycine linker between the ﬂuorescent probe
and the original N-terminus residue. All peptides were resuspended in
10% DMSO at 7.5 mM. Concentration was validated by spectrophotom-
etry when possible. Peptides not containing aromatic residues in their
sequence were assessed by bicinchoninic acid assay (BCA). Cyclosporin
A (CsA)was obtained from Sandoz. Ionomycin (Io) sodium salt, Phorbol
12-myristate 13-acetate sodium salt (PMA) and cycloheximide were
obtained from Sigma. RNAiMAX transfection reagent was purchasedfrom Invitrogen. The anti-calcineurin A antibody was purchased from
BD Biosciences, the anti-CK2α (H-286 clone) from Santa Cruz, and the
anti-HA (Clone 12CA5) and monoclonal anti-α-tubulin (P-6074) were
from Sigma. The protease and phosphatase inhibitor cocktails were
from Calbiochem.
2.2. Plasmid constructs and site-directed mutagenesis
The different pGEX5X–RCAN3, pGEX6P–CnA (human CnAα
amino acids 2–347), HA–RCAN3 (NP_038469.1) and HA–RCAN1
(NP_004405.3) plasmid constructs used for this work have been de-
scribed previously [8]. RCAN2-3 cDNA (NM_001251973.1) was a gift
from Dr. X. Cao and was subcloned as an N-terminal HA-tagged fu-
sion in pcDNA3.1-HA vector using BamHI restriction sites. The
Flag–hCnAα and GST–NFATc2 expression plasmids were kindly pro-
vided by Dr. J. M. Redondo (CNIC, Madrid, Spain), the 3xNFAT-luc
plasmid construct by Dr. J. Aramburu (Universitat Pompeu Fabra,
Barcelona, Spain), and the pRL-null plasmid, which lacks a promoter
driving Renilla expression, from Dr. C. Marín (Universidad de
León, León, Spain). The EGFPc–RCAN3178–203 construct has been
previously described [12]. The RCAN3178–210 protein fragment was
PCR-ampliﬁed from the HA–RCAN3 plasmid using speciﬁc primers
and subcloned as an EGFPc-fusion protein using BamHI restriction
sites. Oligonucleotide sequences are listed in Supplementary Table 1.
2.3. Recombinant protein expression and puriﬁcation
GST fusionproteinswere transformed inBL21-CodonPlus®strain. Sol-
uble extracts were produced and GST fusion protein was puriﬁed using
Glutathione Sepharose 4B beads (GE Healthcare) as described previously
[21]. Free CnAwas obtained byPrescission protease (GEHealthcare) incu-
bation of the puriﬁedGST–CnA.Quantiﬁcation, integrity andpurity of CnA
were assessed by spectrophotometry and 10% SDS-PAGE.
2.4. Cell lines and transfection
Human Jurkat T-cells were maintained in RPMI with Glutamax
(Invitrogen) supplemented with 10% fetal bovine serum (FBS). HEK
293T cells were maintained in DMEM with Glutamax (Invitrogen)
supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml
streptomycin. For immunoprecipitation and reporter gene assays,
HEK 293T cells were transfected with the indicated plasmids using
polyethyleneimine (PEI)-mediated transfection. Brieﬂy, plasmid DNA
and PEI (linear 25,000 MW polyethyleneimine, Polysciences) were
added in separate tubes to 0.9% NaCl. Then, DNA–PEI complexes (DNA:
PEI ratio of 1:2.5 (w:w)) were prepared by adding PEI solution to the
DNA and immediately vortexing for a short time. After 20 min incubation
at room temperature, complexes were added to the cells. The following
day, the medium was replaced and the cells were left incubating at
37 °C for an additional 24 h. For luciferase assays, cells were analyzed
24 h post-transfection. One day before HA–RCAN3 plasmid transfection,
pooled siRNA against CK2α (Dharmacon) was transfected in HEK 293T
at 25 nM with RNAiMAX reagent (Invitrogen) following the
manufacturer's instructions to deplete CK2α in the cells.
2.5. NFAT-luciferase reporter gene assay
HEK 293T cells were seeded at 30% conﬂuence in 24-well plates.
24 h later, each well was transfected with 100 ng of 3xNFAT-luc re-
porter plasmid, 0.9 ng of pRLNull as an internal transfection control
and decreasing concentrations of the indicated constructs (200 ng,
20 ng, 2 ng and 0.2 ng for HA–RCAN3 and 500 ng, 250 ng, 125 ng
and 62.5 ng for the EGFPc–RCAN3178–210). The total amount of plas-
mid DNA was kept constant in all conditions using empty vector.
24 h after transfection, cells were stimulated with 1 μM ionomycin,
10 ng/ml PMA and 10 mM CaCl2. Cyclosporin A (CsA, 1 μM) was
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ulation, cells were analyzed for luciferase gene expression using the
Dual-Luciferase Reporter Assay (Promega) following the manufac-
turer’s protocol on a multiplate luminometer (FLUOstar Optima,
BMG). Luciferase units were normalized to Renilla luciferase values.2.6. In vivo phosphorylation
HA and EGFP-tagged protein constructs were transfected in HEK
293T cells in 6-well plates for RCAN1 and RCAN3 and in p100 dishes
for RCAN2 and EGFP–CIC in vivo phosphorylation. After 24 h, cells
were incubated in phosphate-free DMEM (Invitrogen) supplemented
with 10% dialyzed FBS for 3 h. Then, cells were labeled with 1 ml for
p6-well plates and 5 ml for p100 dishes of phosphate-free DMEM
supplementedwith [32P]Pi at a concentration of 50 μCi/ml for additional
3 h. Where indicated, CX-4945 was added at 10 μM to the culture me-
dium 16 h prior to immunoprecipitation. Cells were then washed in
cold phosphate buffered saline (PBS) and lysed in ice-cold RIPA buffer
(50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% TX-100, 5 mM EGTA, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM PMSF and protease and phos-
phatase inhibitor cocktails). Protein extracts were centrifuged at
16,000 ×g at 4 °C and the soluble HA or EGFP-tagged proteins from su-
pernatants were immunoprecipitated by incubation with anti-HA or
anti-GFP coupled to protein G Sepharose beads (GE Heatlhcare) in a
rocking platform for 1 h in ice. Beads were washed extensively in
RIPA buffer, resuspended in 2× Laemmli sample buffer and boiled for
10 min. Immunoprecipitated proteins were resolved on 10% SDS-PAGE,
transferred onto nitrocellulose membranes and subjected to autoradiog-
raphy (CL-XPosure Film, Thermo Scientiﬁc). Later, membranes were in-
cubated with anti-HA antibody (1:1000, 1 h at room temperature) or
anti-GFP (1:1000, 1 h at room temperature) and the signals were quan-
tiﬁed to normalize the radioactive signal of the immunoprecipitated
proteins.2.7. GST-pull-down competition assays
In GSTRCAN3 pull-down competition assays, HEK 293T cells were
lysed in co-immunoprecipitation buffer (50 mM Tris–HCl, pH 7.5,
100 mM NaCl, 2 mM CaCl2, 5 mM MgCl2, 1% IGEPAL, 1 mM DTT,
2 mM PMSF and protease and phosphatase inhibitor cocktails) and
the CIC-derived peptides were added to the extracts at the indicated
concentrations for 20 min. Then, the soluble extracts were incubated
with GST–RCAN3 bound to Glutathione Sepharose beads for 1 h
at 4 °C. After extensive washing, co-precipitated proteins were eluted
by resuspension in 2× Laemmli buffer and boiling for 10 min. For
GST–NFATc2 pull-down competition assays, HEK 293T cells transfected
with FLAG–CnA were lysed in a buffer containing 50 mM Tris–HCl,
pH 8, 100 mM NaCl, 1.5 mM CaCl2, 6 mM MgCl2, 0.2% TX-100, 1 mM
PMSF and protease and phosphatase inhibitor cocktails.2.8. In vitro CK2 kinase assay
Phosphorylation of wild-type and mutant GST–RCAN3 constructs
(7.5 μg each) was carried out for 60 min at 30 °C in a medium
containing human His6–CK2 holoenzyme (reconstituted by mixing
1.25 pmol His6–CK2α and 1.25 pmol His6–CK2β) or of His6–CK2α
alone (1.25 pmol) and 100 μM of [γ-32P] ATP. The reactions were
stopped by adding 2× Laemmli buffer and boiling, resolved onto a
12% SDS/PAGE and analyzed by autoradiography. Coomassie blue
staining of the gel was performed to ensure equal amounts of pro-
tein in the assay. The activity of the reconstituted enzymes was test-
ed previously using the CK2 substrate peptide RRRADDSDDDDD
(Jena Bioscience).2.9. Fluorescence polarization
To calculate Cn-binding afﬁnities, 10 nM of CF-labeled peptide
in 50 μl of PBS (pH 7.4) containing 1% (w/v) fraction V bovine serum
albumin (BSA) (Roche Diagnostics, IN) was titrated with increasing
concentrations of puriﬁed CnA. For the competitive binding assays,
the peptide–CnA complex was performed using 10 nM CF-labeled pep-
tides and 4 μMCnA for the CF–RCAN3183–203, CF–RCAN3183–208 and CF–
phosphoRCAN3183–208 peptides and 10 μMCnA for the CF–SPRIEIT pep-
tide. Unlabeled competitor peptides were pre-incubated with CnA at
increasing concentrations for 15 min before adding the ﬂuorescence-
labeled peptides. Experiments were performed in a OptiPlate black
384-well ﬂat-bottom plates (PerkinElmer Life Sciences, Waltham, MA)
and measured using a Wallac VICTOR™ X5 2030 Multilabel Reader
(PerkinElmer Life Sciences) with excitation and emission wavelengths
of 485 nm and 535 nm, respectively. All binding and competition as-
says were performed for 15 min at room temperature. All data were
obtained from at least three independent experiments performed in
triplicates.
2.10. Circular dichroism
CD spectra were recorded at 20 °C and 5 °C on a Jasco J-810
spectropolarimeter (JASCO Corporation, Tokyo, Japan) in quartz cells
of 0.1 cm path length. Peptides were dissolved at 20 μM in PBS and
their ability to adopt a secondary conformation was analyzed by
MeOH and 2,2,2,-triﬂuoroethanol (TFE) titrations. Each CD spectrum
was the average of 20 scans performed at 1 nm intervals. The results
are expressed as mean molar residue ellipticities (deg cm2 dmol−1).
2.11. Lentiviral production, puriﬁcation and infection
The lentivirus encoding EGFP-fusion peptides (pWPT, Addgene:
12255) were obtained by transient calcium phosphate transfection of
HEK 293T cells. At 48 h post-transfection the supernatants of the
transfected cells were collected, ﬁltered through a 45 μM membrane
and ultracentrifuged at 20,000 rpm for 1.5 h in a SW-28 rotor
(Beckmann Coulter). Concentrated viruses were collected in cold PBS
and stored frozen at −80 °C. Exponentially growing Jurkat cells were
transduced overnight at MOI = 10 at a cell density of 500,000 cells/ml
in RPMI supplemented with 10% FBS and 8 μg/ml polybrene. At 16 h
post-infection, the medium was replaced with fresh RPMI 10% FBS.
2.12. Cell sorting
Transduced Jurkat cells were resuspended (107 cells/ml) in PBS
supplemented with 0.5% BSA and 2 mM EDTA to prevent cell aggre-
gation. The EGFP positive population was sorted in three different
groups depending on the protein levels of EGFP using MoFlo Astrios
equipment (Beckman Coulter, Scientiﬁc Services at the University of
Barcelona). The same sorting windows were applied for the two
EGFP–peptide expressing cells. Cells expressing EGFP alone at the
window corresponding to the highest level of EGFP protein were
used as controls. Sorted cells were recovered in fresh RPMI 10% FBS
and incubated at 37 °C, 5% CO2 and 95% relative humidity until they
were assayed.
2.13. RNA extraction and real-time PCR
Sorted Jurkat cells were stimulated for 4 h with 1 μM ionomycin
and 10 ng/ml PMA. Then, the cells were pelleted and RNA was
extracted using RNAeasy kit (Quiagen). At least 300 ng of RNA was
used to synthesize cDNA using Superscript III (Invitrogen) following
themanufacturer's protocols. Quantitative PCR (qPCR) experimentswere
performed using Universal probe Libraries (UPL, Roche) followingmanu-
facturer’s instructions. PCR reactions were carried out in triplicates in a
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used as a housekeeping control. The human UPL probes used for
real-time experiments were UPL probe 65 for IL2, UPL probe 81 for
RCAN1-4, UPL probe 21 for IFNγ, UPL probe 60 for IL3, UPL probe 3 for
CSF2, UPL probe 29 for TNF-α and UPL probe 73 for HPRT1. The primers
used are shown in Supplementary Table 1.
2.14. In silico modeling
Template complexes of the interaction between CnA and VIVIT pep-
tides were extracted from the Protein Data Bank database (PDB) [35]
and used to model the interaction of several peptides similar to VIVIT.
As a template we used the complex structure of PDB ID: 2P6B, a 2.3 Å
X-ray structure of Cn bound with the optimized NFAT-derived VIVIT
peptide. The structures of four different peptide sequences were
modeled on its interaction with CnA using the MODELLER program
[36]. A total of 500 models were generated with the MODELLER for
each peptide–CnA complex. For the sake of comparison, the template
was also modeled upon itself to obtain a collection of 500 conforma-
tions. Models were evaluated using the distribution of the ZRANK
docking-score [37]. Distributions of ZRANK scores were compared
using a t-test. A threshold of 0.001 of signiﬁcance in the t-test was
used to assess if the distributions were similar or different. To evaluate
the normality of the distributions we used the Shapiro–Wilk test with
0.001 signiﬁcance thresholds. UCSF Chimera package and Pymol [38]
were used for visual inspection of the interactionmodels, for the graph-
ical representations and for the calculation of accessible surfaces. Elec-
trostatic potentials over the accessible surface of Cn were calculated
with Adaptative Poisson–Boltzmann Solver (APBS) software [39].
3. Results
3.1. RCAN proteins are phosphorylated at the conserved CIC motif in vivo
In order to explore the regulatory mechanisms governing the CIC
motif function in the human RCAN proteins more deeply, we focused
on the post-translational modiﬁcations predicted for the RCANs. To beFig. 1. RCAN proteins are phosphorylated at the CIC motif in eukaryotic cells. (A) Scheme sho
protein family (upper) and at the N- and C-termini of RCAN3 (lower scheme). An arrow d
CK2-target S18 in RCAN3. (B–C) Radioactive labeling with [32P]-orthophosphate of the HA
detected by membrane autoradiography. Western blot using anti-HA is shown as a contr
chain and two asterisks (**) to the light IgG chain. Radioactive signal was quantiﬁed by den
ware (Bio-Rad). Densitometry values are presented below each lane as a fraction of the radi
etry values below the panel are expressed as mean with standard deviation (SD) from thespeciﬁc, by using Net Phos 2.0 server [40] we identiﬁed a CK2 phos-
phorylation site at a serine residue within the CIC motif that was con-
served in all vertebrate RCAN proteins (Fig. 1A). Furthermore, there
were two additional sites present exclusively in human RCAN3-2 iso-
form: T205 next to the conserved S203 at the CIC motif of RCAN3 and
T19 at the non-conserved N-terminus. Finally, although not fulﬁlling
the consensus CK2 target sequence, we also considered S18 as a po-
tential phosphorylation site based on other CK2 phosphorylated pro-
teins [31].
Bymeans of in vivo radioactive labeling of transfected HEK 293Twith
[32P]-orthophosphate we observed that human RCAN1-1, RCAN2-3 and
RCAN3-2 isoforms [7] (hereafter referred to as RCAN1, RCAN2 and
RCAN3, respectively) were phosphorylated in basal conditions (Fig. 1B
and C, wild-type (wt) proteins). Additionally, when mutating the two
RCAN2 serine residues at the FLISPP motif (hereafter termed RCAN2
AA, which corresponds to serine residues S158 and S162 mutated to al-
anine) and of the RCAN3 FLISPP motif (hereafter termed R3 AA, which
corresponds to RCAN3 S148 and S152 residues mutated to alanine) the
incorporation of radioactive phosphate by the immunoprecipitated pro-
teins was reduced compared with the wild-type protein (Fig. 1B and C),
indicating that at least one of the serine residues at the FLISPP motif of
RCAN2 and RCAN3 is phosphorylated in vivo. This observation suggests
that the phosphorylation at the CIC motif is independent of that occur-
ring at the FLISPP motif of RCAN proteins.
Also, when the CK2-target serine residue within the CIC motif in the
three RCANs (S218 for RCAN1; S213 for RCAN2 and S203 in RCAN3)
wasmutated to alanine, we observed a reduction in the radioactive signal
conﬁrming that this serine of the CIC motif of all human RCAN is phos-
phorylated in vivo (Fig. 1B and C).
Apart from the CICmotif, mutation of S18 to alanine in RCAN3 also re-
duced its radioactive phosphorylation signal, suggesting that S18 is also
phosphorylated in vivo at basal conditions (Fig. 1C, compare R3AA S18A
vs R3AA). Furthermore, mutating both CK2 predicted phosphorylation
sites in RCAN3 (R3AA S18A/S203A: R3AA with the additional mutations
to alanine at S18 and S203) resulted in a further reduction in the incorpo-
ration of radioactivity by themutant protein (Fig. 1C, compare R3AAwith
R3AA S18A/S203A). Mutating T19 and T205 to alanine in the R3AA S18A/wing the predicted CK2 target sequence (S/TxxE/D) at the CIC motif of the human RCAN
esignates the conserved CK2-target serine residue at the CIC motif and an asterisk the
-RCAN wt or mutant proteins transfected in HEK 293T cells. [32P] incorporation was
ol of the immunoprecipitated protein. One asterisk (*) corresponds to the heavy IgG
sitometry and normalized to the immunoprecipitated protein using Quantity One soft-
oactive phosphorylation signal referred to the signal in the wt protein. In 1C, densitom-
indicated number of experiments performed (n).
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incorporation of a radioactive signal, suggesting that these residues
might also be phosphorylated in vivo. Finally, since R3AA S18A/T19A/
S203A/T205A is still phosphorylated, it is suggested that there is at least
one additional phosphorylated site in the protein in basal conditions.
3.2. Protein kinase CK2 phosphorylates the CIC motif of the RCANs in
vitro
It has been reported that both the tetrameric CK2 enzyme and the
CK2α and CK2α′ free subunits are catalytically active in vitro [31]. In
order to differentiate whether the CK2 holoenzyme (CK2αβ) or the
free CK2α catalytic subunit were able to phosphorylate RCAN3 at
the predicted phosphoacceptor sites, we performed a kinase assay
by incubating RCAN3 wild-type (wt), RCAN3 N-term (amino acids 2
to 144) and RCAN3 C-term (amino acids 176 to 241) with either
CK2 holoenzyme or free CK2α catalytic subunit. First, we observed
that both CK2 forms phosphorylated RCAN3 wt protein (Fig. 2A). Im-
portantly, RCAN3 wt protein showed a stronger radioactive signal
when phosphorylated with the holoenzyme as compared with the
phosphorylation with CK2α alone (Fig. 2A, compare lanes 3 and 4).
Secondly, we observed that the N-terminus of RCAN3 was preferen-
tially phosphorylated by CK2α whereas the C-terminus of RCAN3
was preferentially phosphorylated by CK2 holoenzyme, highlighting
a role for CK2β regulatory subunit in the phosphorylation of the con-
served region of RCAN3.
In accordance with what was observed in eukaryotic cells, radioactive
labeling due to CK2 holoenzyme phosphorylation was absent when mu-
tating the RCAN3 CK2 predicted phosphorylation sites, i.e. S18A/T19A at
the N-terminus and S203A/T205A at the C-terminus of RCAN3 protein
(Fig. 2B). Moreover, in the same kinase assay the C-terminus of RCAN1
(amino acids 170 to 252) was also phosphorylated by CK2 in vitro
(Fig. 2B, lane 8), suggesting a conserved feature of the RCAN protein fam-
ily. Point mutations at the C-terminus of RCAN3 identiﬁed position S203
of RCAN3 located within the conserved CIC motif, as the preferential tar-
get for CK2 phosphorylation (Fig. 2C). Additionally, we detected a weak
phosphorylation signal in the S203A mutant, suggesting that T205 could
also be phosphorylated, but to a much lesser extent than S203. The ab-
sence of radioactive signal in the S203A/T205A mutant conﬁrmed that
there are no other CK2 target sites in the conserved C-terminus of RCAN3.
3.3. Protein kinase CK2 phosphorylates the CIC motif of RCAN proteins in
vivo
In order to determine if CK2 could be involved in RCAN phosphor-
ylation at the CK2 predicted sites in vivo, HEK 293T cells transfectedFig. 2. Protein Kinase CK2 phosphorylates human RCAN proteins including the CIC motif in
fusion proteins and deletion mutants in the presence of radioactive [γ-32P]-ATP. Coomass
(A) GST-RCAN3 fusion protein (wt) and deletion mutants were incubated with either pu
GST–RCAN3175–241. (B and C) GST–RCAN3 (R3) and the indicated mutants and GST–RCAN
RCAN1170–252.with RCAN1 and RCAN3, either wt or mutated at the conserved serine
residue at the CIC motif were radiolabeled in the presence of a speciﬁc
CK2 inhibitor CX-4945 [41,42]. As shown in Fig. 3A, incubating the
cells with CX-4945 dramatically reduced the radioactive phosphate
incorporation to RCAN1 and RCAN3 proteins. When mutating the
CK2 target residue of RCAN1 protein we observed reduced phosphor-
ylation of the protein and most importantly, its radiolabeling levels
were not further reduced in the presence of CX-4945. A similar phos-
phorylation proﬁle is observed in RCAN1 when transfecting the cells
with a speciﬁc siRNA against CK2α (Fig. 3B), where there is no further
reduction of RCAN1 S218A phosphorylation in the presence of siRNA
CK2α, which conﬁrms that this residue is the only target site for CK2
for RCAN1. These results suggest that S218 in RCAN1 is the only res-
idue phosphorylated by CK2 in eukaryotic cells and therefore subject
to the effects of the CK2 inhibitor. As for RCAN3, incubation with
CX-4945 did reduce the phosphorylation status not only of the wt
protein but also of the mutated protein at the conserved S203,
suggesting that there are other CK2 dependent phosphorylation
sites in RCAN3. In accordance with this, RCAN3 presents at least one
extra CK2 target site at the N-terminus of the protein, S18, as
shown in Figs. 1A and 2B. CK2α depletion has a much smaller effect
on RCAN3 phosphorylation probably due to the presence of addition-
al phosphorylation sites targeted by CK2 and/or other kinases (data
not shown). Taken together our results strongly suggest that the pro-
tein kinase CK2 phosphorylates a conserved serine residue within the
CIC motif of human RCAN proteins. However, we cannot rule out the
possibility that other kinases could also be involved in the regulation
of the conserved serine residue at the CIC motif.
3.4. The phosphorylation at the CIC motif of RCANs increases the disruptive
potential of the motif towards the Cn–NFATc interaction
It has been previously described that, in addition to the CIC motif,
the central region of RCAN proteins contributes to the binding and in-
hibition of Cn [13]. In order to exclude a masking effect by these other
regions in the context of the full-length protein, we studied the ef-
fects of CK2 phosphorylation on Cn binding using the CIC motif of
RCAN3 alone. Thus, an experiment was set up to deﬁne the binding
afﬁnities for CnA of the CIC-derived peptides by ﬂuorescence anisot-
ropy. This extended what had been previously described as the min-
imal NFATc-inhibitory sequence in RCANs, the R3183–203 peptide [12],
at its C-terminus to include the CK2 target sequence when phosphor-
ylated or not (that is RCAN3183–203, RCAN3183–208 and RCAN3183–208
phosphorylated at S203).
We found that the Kd value of the CF-phosphoR3183–208 peptidewhen
binding to CnA was lower compared with the non-phosphorylatedvitro. In vitro CK2 phosphorylation assay using recombinant GST-RCAN3 or GST-RCAN1
ie gel staining is shown as loading control. GST alone was used as negative control.
riﬁed human CK2α or CK2 holoenzyme (CK2αβ). N-term: GST–RCAN32–144; C-term:
1 C-terminus (R1 C-term) were incubated with CK2 holoenzyme. R1 C-term: GST–
Fig. 3. Protein kinase CK2 phosphorylates the CIC motif of human RCAN proteins in vivo. HA-RCAN1 or HA-RCAN3 or the indicated mutants were transfected into HEK 293T cells and
then radioactive incorporation was analyzed in the presence of the CK2 inhibitor CX-4945 (A) or siRNA against CK2α (B). After incubation with radioactive phosphate for 3 h, im-
munoprecipitation was carried out using anti-HA antibody. Radioactive labeling of the proteins was detected by membrane autoradiography. CK2 was detected by using the
anti-CK2α antibody. Western blot using anti-HA is shown as a control of the immunoprecipitated protein and anti-α-tubulin as a loading control. Radioactive signal was quantiﬁed
by densitometry and normalized to the immunoprecipitated protein using Quantity One software (Bio-Rad Densitometry values is presented below each lane as a fraction of the
radioactive phosphorylation signal referred to the signal in the wt protein. An asterisk (*) corresponds to the heavy IgG chain. IP: immunoprecipitation.
Fig. 4. Phosphorylation of the CIC motif at the conserved CK2 target site increases its potential to disrupt Cn–NFATc interaction. (A) Binding of CF–R3183–203, CF–R3183–208
and CF–phosphoR3183–208 peptides to increasing amounts of CnA assessed by ﬂuorescence anisotropy. Anisotropic ﬂuorescence emission values (mP) are represented as
mean ± SEM of three independent experiments performed in triplicates. (B) SPRIEIT–CnA interaction was competed with increasing amounts of unlabeled R3183–203,
R3183–208 and phosphoR3183–208 peptides. An unrelated peptide was included as negative control. Data is represented as mean percentage of CF–SPRIEIT bound to CnA
(±SEM) of three independent experiments performed in triplicates. Signal in the absence of competing peptide was considered as 100% of CF–SPRIEIT bound to Cn. Appar-
ent KD (A) and IC50 (B) values for all the interactions are displayed below each graph respectively. (C–D) Endogenous CnA (C) or Flag–CnA (D) coprecipitation assays using
GST–RCAN3 (C) or GST–NFATc2 (D) as bait and competed with increasing concentrations of CIC-derived peptides. GST alone was used as negative control. Ponceau staining
of the membrane shows equal GST fusion protein loading of each lane.
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CF-R3183–208 = 3.3 ± 0.04 μM and CF-phosphoR3183–208 = 2.36 ±
0.03 μM), suggesting a higher afﬁnity of CF-phosphoR3183–208 peptide
for CnA. The speciﬁcity of the interaction with CnA of each peptide is
shown in Supplementary Fig. 1. Then, we analyzed how the different
CIC-derived peptides, which include a PXIXIT-like motif, were able to
disrupt the Cn–NFATc complex. We performed competition assays
where the complex formed by Cn and a peptide spanning the PXIXIT se-
quence of NFATc2 (termed SPRIEIT), was competed with unlabeled
R3183–203, R3183–208 or phosphoR3183–208. The results showed that
the extended peptide R3183–208 was similar to R3183–203 (Fig. 4B; IC50
for R3183–203 = 2.66 ± 0.12 μM vs R3183–208 = 3.46 ± 0.12 μM).
However, when the R3183–208 peptide was phosphorylated at the con-
served serine (i.e., phosphoR3183–208) the IC50 value was lower than
the non-phosphorylated R3183–208 and R3183–203 peptides (IC50 phos-
phoR3183–208 = 1.78 ± 0.18 μM) indicating that it is the best compet-
itor of the peptides examined. These results were further analyzed in
a cellular context by performing a competitive pull-down analysis, in
which increasing amounts of CIC-derived peptides where incubated
with the complex formed by CnA and either GST–RCAN3 or GST–
NFATc2, both containing a PXIXIT motif. In line with the IC50 values
obtained above, the phosphoR3183–208 proved to be a better competi-
tor, compared with either R3183–203 or R3183–208, of any of these pro-
teins in complex with CnA (Fig. 4C and D). It is worth noting that the
enhanced disruptive potential of the phosphoR3183–208 was best ob-
served over the CnA–NFATc2 complex (Fig. 4D). Taken together, our
data strongly suggest that the phosphorylation of the CIC motif of
RCAN proteins enhances the disruptive potential of a CIC-derived pep-
tide towards the Cn–NFATc interaction.
3.5. Phosphorylation of the CIC motif of the RCANs enhances its inhibitory
potential towards Cn–NFATc signaling
In order to test the extent to which this increased inhibitory activ-
ity of the phosphoR3183–208 translated into a downstream signaling
outcome, we compared the CIC- and phosphoCIC-derived peptides
in their ability to inhibit NFATc-dependent promoter activation. HEK
293T cells transfected with the EGFP fusion peptides encoding for
R3178–203, R3178–210 and R3178–210 S203A and radiolabeled using
[32P]-orthophosphate showed that the EGFP-R3178–210 peptide is
phosphorylated in vivo. In contrast, neither the EGFP nor the EGFP–
R3178–203 (lacking the CK2 phosphorylation target sequence) was
phosphorylated (Fig. 5A). In line with our previous observations, mu-
tation at S203 of the EGFP–R3178–210 peptide dramatically diminished
the radioactive labeling. Interestingly, we also observed a faint phos-
phorylation signal in the EGFP–R3178–210 S203A peptide, suggesting
that other residues in the extended peptide, most likely T205, might
also be phosphorylated. Next, we transfected the EGFP fusion peptides
encoding for R3178–203, R3178–210, R3178–210 S203A and R3178–210
S203E sequences together with an NFATc-dependent luciferase
gene reporter plasmid in HEK 293T cells (Fig. 5B). We observed
that R3178–203, which does not include the C-terminal CK2 phosphoryla-
tion target sequence, had a decreased ability to inhibit NFATc promoter
activation as compared to the extended R3178–210 peptide, where S203
is phosphorylated. Furthermore, the R3178–210 S203A peptide produced
a similar inhibitory proﬁle as the R3183–203 peptide, whereas mutating
the S203 to glutamic acid, mimicking a negative charge at that position,
increased the NFATc-inhibitory effect of the peptide. Altogether, these
results point to an important role for the phosphorylated residue in
the inhibition of NFATc activation.
Additionally, we analyzed how the phosphorylated CIC motif
could inﬂuence the expression of NFATc-dependent genes by
real-time PCR in Jurkat cells after stimulation with ionomycin and
PMA for 4 h. To do so, we previously transduced the cells with a len-
tivirus encoding either the EGFP–R3178–210 or EGFP–R3178–210 S203A
peptides and sorted them in three different groups depending ontheir level of EGFP–peptide expression. At lower levels of EGFP–
RCAN peptide the inhibition of NFATc dependent transcription was
not saturated (data not shown) and therefore we only used this pop-
ulation for the analysis. As shown in Fig. 5C, the phosphorylated
R3178–210 peptide signiﬁcantly inhibited IL2, IL3, CSF2 and RCAN1-4
and to a lower extent IFNy gene expression. In sharp contrast, the mu-
tated R3178–210 S203A peptide, even though it conserves an intact
PXIXIT sequence, was less efﬁcient in the inhibition of NFATc depen-
dent gene expression. It is worth noting that not all NFATc genes were
equally altered by the phosphorylation status of the CIC peptide
(compare IL2 vs TNF-α), suggesting a gene-speciﬁc regulatory role
for the phosphorylation of the CIC motif of RCAN proteins on the out-
put signal of an activated Cn–NFATc signaling pathway.
3.6. A negatively charged tail C-terminal to the RCAN3 PXIXIT-like
sequence enhances the disruption of Cn–NFATc interaction
Since no structural information is available for the RCAN–CnA in-
teraction, we modeled the R3192–204–CnA interaction based on the
previously described VIVIT–CnA crystal structure (PDB: 2P6B) [17].
Two different sequences were used to model each CIC-derived pep-
tide: i) only the PXIXIT core sequence (Supplementary Fig. 2A,
underlined sequence) and ii) the PXIXIT core sequence plus addition-
al C-terminal amino acid residues. We calculated the correlation be-
tween experimental binding afﬁnities of different PXIXIT sequences
and ZRANK mean values (Supplementary Fig. 2A). It has to be noted
that in accordance with the observed signiﬁcant correlation between
experimentally determined afﬁnity and average of ZRANK scores, the
authors of ZRANK have used a similar approach to generalize the ap-
plication to predict the afﬁnity of protein–protein interactions [37].
The Spearman's rank correlation was 0.70 (with signiﬁcant p-value
b0.01) when using the PXIXIT core motif alone. This correlation in-
creased to 0.83 (with signiﬁcant p-value = 0.003) when using longer
peptides (extended 4 or 5 residues in C-terminus and 2 residues in
N-terminus). In summary, these results suggest a signiﬁcant correla-
tion between the experimentally determined afﬁnity and average of
ZRANK scores of the models of the interaction between peptides
and Cn.
The structure of the peptide sequence R3192–204 with a mutation at
S203 to aspartic acid (R3192–204 S203D, STPSVVVHVCEDE) was
modeled to mimic the effect of a negative charge, provided by the
phosphorylation of the conserved serine at the C-terminus of the pep-
tide when it interacts with CnA. We also modeled a mutated VIVIT
peptide with the two C-terminal glutamic acids substituted by ala-
nine (VIVIT–AA) and compared it with the original VIVIT peptide
with a double negative charge at position +4 and +5 from the
PXIXIT motif (MAGPHPVIVITGPHEE), which is at the same distance
as the phosphorylated serine from the PXIXIT sequence of RCANs.
The distribution of scores of the interaction of R3192–204 peptide
with Cn was signiﬁcantly higher than the distribution of R3192–204
S203D, which suggests an increased binding afﬁnity for R3192–204
S203D as compared to R3192–204 (Supplementary Fig. 2b; p-value
b0.01). These results suggest that the presence of negatively charged
residues in the C-terminal region of the peptide increase its binding
afﬁnity for Cn.
The graphical representation of the model of the R3192–204 S203D
peptide interacting with CnA shows the location of the D203 residue
facing a positively charged area of CnA (Fig. 6A). To be precise, K100
and N335 in CnA lie at 4 Å from the D203 in the RCAN3-derived pep-
tide, whereas R332 and Q333 are 5 Å away. Also in the model, E202 of
the RCAN3-derived peptide could help to position the side-chain of
H199 to pack against the guanidium group of R332 in CnA. As
shown in Fig. 6B, the C-terminus of the VIVIT peptide in the 2P6B
structure is also facing the aforementioned positively charged surface
of Cn. Therefore, it is suggested that the electrostatic complementar-
ity between this positively charged region of CnA and a C-terminal
Fig. 5. Phosphorylation of the CIC motif at the conserved CK2 target site increases the inhibition towards the Cn–NFATc signaling pathway. (A) Radioactive labeling with [32P]-or-
thophosphate of the EGFP fusion peptides encoding for R3178–203, R3178–210 and R3178–210 S203A in HEK 293 T cells. [32P] incorporation was detected by membrane autoradiogra-
phy. Western blot using anti-EGFP is shown as a control of the immunoprecipitated protein. (B) Luciferase reporter gene assays in HEK 293T cells transfected with 3xNFAT-luc
plasmid and increasing concentrations of EGFP–R3178–203, EGFP–R3178–210, EGFP–R3178–210 S203A and EGFP–R3178–210 S203E fusion peptides. Data is one representative experiment
(N = 3) given as mean (±SEM) percentage of NFAT activation where the 100% is the activation achieved by the mock vector with ionomycin (Io)/PMA/CaCl2 alone. The expression
of each construct in each condition was assessed by western blot using anti-EGFP antibody. (−) no stimulation; (+) stimulated with Io/PMA/Ca2+; (CsA) stimulated with Io/PMA/
Ca2+/cyclosporine A. (C) Gene expression of IL2, IL3, IFNγ, TNFα, CSF2 and RCAN1-4 was analyzed by real-time PCR in transduced Jurkat cells after Io/PMA/Ca2+ stimulation. Jurkat
cells were previously transduced with a lentivirus encoding either EGFP alone, EGFP–R3178–210 or EGFP–R3178–210 S203A fusion peptides. The three groups were sorted under the
same criteria depending on the level of EGFP expression. Data is represented as mean (±SEM) fold change of mRNA levels relative to that obtained in the EGFP expressing group in
stimulating conditions (dashed line). T-test was used for statistical analyses compared to EGFP expressing control group (N = 3). *p b 0.05; **p b 0.01; ***p b 0.001.
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the binding afﬁnity of the peptides for CnA. Furthermore, circular di-
chroism (CD) spectroscopy revealed that the two peptides, R3183–208
and phosphoR3183–208, adopt random conformation in phosphate
buffer solution (Supplementary Fig. 3). However, when analyzed in
TFE or MeOH, both of which act as secondary structure stabilizers,
R3183–208 showed a partial ability to populate β-sheet conformation
while peptide phosphoR3183–208 proved to be less structured in
these conditions. Thus, it is tempting to speculate that peptide phos-
phoR3183–208 could display a less rigid environment-dependent con-
formational adaptability to the Cn interacting surface than peptide
R3183–208.
Finally, in accordance with the modeling of the CIC derived pep-
tide, the VIVIT peptide was also predicted to have a higher afﬁnity
for CnA compared to VIVIT–AA, the distribution of energies being
lower for VIVIT than for VIVIT–AA (Supplementary Fig. 2B). This
model was conﬁrmed experimentally, as we observed that the ab-
sence of a double negative charge at +4 and +5 of the PXIXIT con-
sensus sequence increased the IC50 value of the VIVIT–AA peptide
to displace the CF–SPRIEIT–CnA interaction more than three times
as compared to the VIVIT wt (Fig. 6C; IC50 for VIVIT = 0.57 ±
0.15 μM vs VIVIT–AA = 1.78 ± 0.13 μM). This difference observed
in the IC50 value implied a dramatic reduction in the ability to disrupt
the Cn–NFATc2 interaction (Fig. 6D). As a conclusion, our results sug-
gest that the inhibitory potential of the VIVIT peptide not only relies
on the optimized sequence of the consensus PXIXIT sequence, but is
also strongly determined by the negative charge at position +4 and
+5 of the PXIXIT core sequence.4. Discussion
In this work we present a novel regulatory mechanism governing
the modulation of the Cn–NFATc signaling pathway by the RCANs.
Our data show for the ﬁrst time that protein kinase CK2 is able to
phosphorylate a conserved serine adjacent to the PXIXIT-like se-
quence within the CIC motif of RCANs. The functional consequence
of such phosphorylation is an enhanced binding of the CIC motif to
Cn, providing a stronger inhibitory potential of the RCANs towards
Ca2+-dependent NFATc activation and therefore NFATc-dependent
gene expression. It is unknown whether this phosphorylation could
also play a facilitative role of the Cn–NFATc pathway provided by
the RCANs [24].
We have identiﬁed a phosphorylation site adjacent to the
PXIXIT-like sequence of RCANs as a novel regulatory element modu-
lating the binding of the motif towards Cn. To be precise, the disrup-
tion of the Cn–RCAN3 or Cn–NFATc interaction obtained with a
phosphorylated R3183–208 peptide is higher than when these interac-
tions are competed with a non-phosphorylated R3183–208 peptide
(Fig. 4). In addition, the presence of a negative charge at the CK2 tar-
get serine increases the inhibitory potential of the CIC motif on a
NFATc-dependent luciferase gene promoter (Fig. 5B). Conversely,
when mutating the conserved serine to alanine in the peptide,
R3178–210 S203A, there is a reduction of the NFATc-inhibitory activity
and consequently in the expression of NFATc-dependent genes upon
T-cell activation (Fig. 5C). Interestingly, while the R3178–210 peptide at
non-saturating conditions inhibited the gene expression of most of
the NFATc dependent genes assayed, the R3178–210 S203A peptide
Fig. 6. An acidic tail C-terminal to the PXIXIT sequence enhances the Cn–NFATc disruptive potential of PXIXIT-derived peptides. (A) Structural representation of the best ZRANK
ranked model of Cn–R3194–204 S203D interaction. Cn surface is colored by electrostatic potential: Blue (positive) and red (negative). Peptide is shown using stick representation.
The C-terminal region of the peptide is faced in a positively charged area in the Cn surface. (B) The acidic tail of the VIVIT peptide in the 2P6B structure faces the same positive
surface of Cn as R3194–204 S203D. (C) SPRIEIT–CnA interaction competed with either VIVIT or VIVIT–AA peptides. Data is presented as in Fig. 4b. Apparent IC50 values for each pep-
tide are displayed on the right. (D) Flag-CnA coprecipitation using GST–NFATc2 as bait competed with either VIVIT or VIVIT–AA peptides performed as in Fig. 4d. (E) Proposed new
model for the CK2 mediated regulation of the Cn–NFATc signaling pathway via phosphorylation of the CIC motif of RCAN proteins. A regulator of RCAN protein dephosphorylation is
unknown (X in the scheme). P indicates a phosphate group; CK2: protein kinase CK2; CK1: protein kinase CK1; DYRK1: Dual speciﬁcity tyrosine phosphorylation-regulated kinase
1; GSK3β: Glycogen synthase kinase 3β; Cn: calcineurin; NFATc: Nuclear Factor of Activated T-cells cytosolic.
2319S. Martínez-Høyer et al. / Biochimica et Biophysica Acta 1833 (2013) 2311–2321could still inhibit the expression of IL2, pointing to a dependence on a
high NFATc activity for the expression of this gene. Altogether, these
observations suggest that the non-phosphorylated CIC derived pep-
tides allows for an increased NFATc activity and therefore, the extent
to which the CIC motif phosphorylation inﬂuences NFATc dependent
gene expression may rely on the speciﬁc NFATc activity threshold
that each gene requires for its transcription. Therefore, we postulate
that this phosphorylation is an important determinant in the modula-
tion of the Cn–NFATc pathway by the RCANs in vivo. Moreover, a bio-
informatic search regarding all known vertebrate PXIXIT sequences
yielded no other proteins apart from RCANs bearing a phosphorylable
amino acid at position +4 from the PXIXIT sequence. This observa-
tion suggests that the regulation by phosphorylation of the PXIXIT
afﬁnity to Cn is exclusive to the RCANs. Previous work from our labo-
ratory has set up the experimental basis for a drug screen based on
the Cn–RCAN interaction, which as a ﬁrst hit identiﬁed dipyridamole
as a drug with immunosuppressant properties [12]. The observation
that the phosphorylation adjacent to the PXIXIT-like motif increases
the displacement of NFAT from Cn provides a detailed mechanism
of such an interaction and may therefore help in the search for
more selective and potent immunosuppressant drugs.
We took advantage of the crystallographic data from the VIVIT in-
teraction with Cn [17] to model the interaction of the CIC motif with
Cn. The model predicted that the PSVVVH sequence would interact ina similar fashion to the VIVIT peptide (Fig. 6A and B). Moreover, the
phosphorylated serine at +4 from the PXIXIT sequence would lie in
close contact with a positively charged region in CnA, that is, within
4 Å distance from a positive charge provided by the K100 residue of
CnA. The interaction between both residues would explain the phos-
phorylation at this position, which adds a double negative charge at
the conserved serine, enhances the interaction of the CIC motif via
an ionic interaction with Cn and therefore increases its Cn–NFATc dis-
ruptive potential. This model of interaction could also explain the
VIVIT–Cn interaction as the mutation of two glutamic acid residues
to alanine at the C-terminus of the VIVIT peptide, even though the
core PXIXIT sequence is intact, dramatically increases the IC50 of the
mutated peptide (Fig. 6C) and its ability to disrupt the Cn–NFATc
complex in cells (Fig. 6D). The data presented here suggest that not
only the sequence deﬁnition of the PXIXIT core, but also the context in
which it is inserted, determines the overall afﬁnity of the motif for Cn.
We have previously described that deleting the ﬁrst three amino
acids (K183, Y184 and E185) of the R3183–203 peptide abrogates its
binding to CnA [12], suggesting that the PSVVVH sequence, probably
due to its high variation from the consensus PXIXIT, needs some other
elements to ﬁrmly anchor to the Cn binding pocket [14]. This de-
creased afﬁnity for Cn could be rescued in RCANs by the negative
charge at the C-terminus of the PSVVVH. It is unknown how the
KYELHA sequence at the N-terminus of the RCAN CIC motif affects
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activity of the CIC motif could be detached in three conserved modules:
i) the KYELHA sequence; ii) the PXIXIT-like sequence, and iii) the
phosphorylable acidic region at the C-terminus. Future studies focused
on solving the crystal structure of the complete CIC motif of RCANs
with Cn would shed light onto the exact role played by each of the
three elements comprising the functional motif in the binding to Cn.
We have shown for the ﬁrst time and by direct means that in addi-
tion to the CIC motif, the FLISPP motif and N-terminus of RCAN3 are
phosphorylated in eukaryotic cells (Fig. 1C). Ongoing studies are ad-
dressing the functional consequences of RCAN3 S18 phosphorylation.
Moreover, our data suggest that protein kinase CK2 phosphorylates
the CIC motif of vertebrate RCANs in vitro and in vivo, although we can-
not rule out the possibility that other kinasesmay be implicated aswell.
Accordingly, the phosphorylated serine identiﬁed at the CIC motif of
human RCAN proteins has also been regarded as phosphorylated in
vivo in Rcan1 and Rcan2 mouse proteins (Phosphomouse database).
We therefore propose a mechanism of regulation of the Cn–NFATc
axis in which the high activity of CK2 counteracts Cn-mediated activa-
tion of NFATc and provides the pathway with a reliable switch to shut
down the signal when activated at two levels: increasing the inhibition
of the Cn-dependent activation of NFATs provided by the RCANs and
priming the nuclear export of NFATc by other kinases [32] (Fig. 6E). It
is unknown whether the phosphorylation at the CIC motif is subject to
regulation by protein phosphatases.
As a conclusion, we present a novel regulatorymechanism bywhich
RCANs modulate the signal output of the Cn–NFATc pathway. We pro-
pose that protein kinase CK2 is responsible for the phosphorylation of
a conserved serine residue adjacent to the PXIXIT-like sequence of ver-
tebrate RCAN proteins, which results in an enhanced binding of the CIC
motif of RCANs to Cn and consequently an increased inhibition of NFATc
signaling in T-cells. Moreover, we have unraveled a novel general regu-
latory mechanism driving the dynamics of the PXIXIT sequence of
RCANs binding to Cn that provides important insights at the molecular
level. We propose that the detailed knowledge of the molecular mech-
anisms governing the PXIXIT–Cn interactionmay also prove very useful
in the rational design of future immunosuppressant drugs.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.05.021.
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